Study Title
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NCT01421667)
Trial description
This is an open-label, multicenter, phase II clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with CD30-positive non-Hodgkin lymphoma (NHL) (Part A). The study will also evaluate the safety and efficacy of brentuximab vedotin in combination with rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Part B) as well as further evaluate correlation of CD30 expression and response in DLBCL (Part C).
This trial is sponsored by Seattle Genetics. [1]
Study data
- Condition: Non-Hodgkin Lymphoma
- Interventions:
- Drugs used in this trial
- brentuximab vedotin (Adcetris®; Seattle Genetics, Inc.)
- rituximab (Rituxam®; Biogen, Inc,/ Genentech, Inc.)
- Phase: II
- Enrollment: 176
- Start: August 2011
- Completion: June 2015
- Last verified: June 2015
Study Schematic
Last Editorial review: July 11, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
